22nd Century Group Inc (NYSEAMERICAN:XXII) will reap huge dividends from an FDA decree. According to the mandate of FDA, all cigarettes sold should have very levels of nicotine. 22nd Century has patents for cigarettes with low nicotine levels. The market for cigarettes with low levels of nicotine is estimated at $124 billion. The company will accrue a large chunk of this market since it has secured patents.

22nd Century is in an advantage with 26 Patents

22nd Century is specialized in breeding and re-engineering of plants mainly in tobacco and on a small scale in cannabis. The re-engineered plants of the company are having very low levels of THC and nicotine. It is the only firm in the world to bag the patents on tobacco products with very low nicotine levels.  The company has already got 26 patents and 23 applications pending.  22nd Century is highly successful in lowering the nicotine levels.

It is the first time that FDA is implementing measures to reduce the harm on cigarette users through lowering nicotine levels and prevent addiction. FDA is pushing for the sale of tobacco products with less harmful components. However, it may take up to 20 years to completely achieve this goal of safer tobacco products for the consumers.

22nd Century Group Inc Wins an Order for 3.6 Million Spectrum Cigarettes From the US Government

22nd Century Group Inc has announced the receipt of an order for 3.6 million spectrum cigarettes from the US FDA, NIDA (National Institute on Drug Abuse), and Public Health Researchers. RTI International has released an order to 22nd Century Group Inc on behalf of the US government and research agencies. This with respect to the promulgation of FDA mandate that all cigarettes sold in the US should have minimal or no nicotine concentration.

Journal of the American Medical Association (JAMA) Publishes Results of Phase III study of cigarettes using Spectrum Very Low nicotine content cigarettes of 22nd Century. The clinical study is conducted to identify the effects of low nicotine cigarettes. The prominent personalities conducted the clinical study include Dr. Dorothy Hatsukami and highly specialized scientists. This study is conducted on 1,250 candidates using cigarettes consisting of 0.4 mg of nicotine and 15.5 mg of nicotine in each gram of tobacco. The users smoked few cigarettes in a day when compared to conventional cigarettes. It also reduced the exposure to toxins.